One of the most common things patients tell me is that they're not sure whether what they're experiencing is normal. This guide explains what clinical evidence and real-world experience shows at each stage of treatment, so you know what's normal, what to watch for, and when something may need reviewing.
Why weight loss on Mounjaro isn't linear
Mounjaro is titrated upward over 20 weeks and weight loss accelerates with each dose increase. There is no single week where results should appear, the trajectory is gradual and cumulative. SURMOUNT-1 ran for 72 weeks. The full benefit is not achieved at week 4 or 12. Understanding this prevents patients from giving up early on a medication that would have worked if they'd continued.
Weeks 1 to 4: 2.5mg dose
The starting 2.5mg dose exists to allow adjustment. It is not a therapeutic weight loss dose. Most patients should not expect dramatic weight loss here. What to notice: reduced appetite, feeling full more quickly, possibly less food noise. You may also notice: nausea, fatigue, changes in bowel habits as your gut adjusts. Weight loss during this period varies significantly between individuals. Some see early changes on the scales, others see little movement. The mechanism is working from day one, but the clinical effects accumulate over weeks and months.
Weeks 4 to 8: 5mg dose
The first therapeutic dose. Appetite suppression becomes more pronounced. Most patients notice eating substantially less without feeling deprived, meals feel satisfying at smaller portions, and the psychological pull of food typically begins to reduce. Weight loss tends to accelerate during this phase for most patients.
Weeks 8 to 20: Titration phase (7.5mg, 10mg, 12.5mg)
The most consistent and often most motivating period. Each dose increase brings a further step up in appetite suppression, and weight loss typically accelerates again after each increase before plateauing briefly. Patients often report the most dramatic reduction in food noise during this phase, the persistent mental preoccupation with eating simply quietens. Based on the overall 72-week trajectory in SURMOUNT-1, patients are typically making meaningful progress by this stage, though the exact pace varies considerably between individuals.
Weeks 20 to 36: Reaching maintenance dose
By week 20, most patients tolerating escalation have reached 12.5mg or 15mg. Weight loss continues steadily but the rate often begins to slow compared to the titration phase, not because the medication has stopped working, but because the body is adapting and a new weight setpoint is being established. This requires patience. Weekly loss may slow, but this represents the medication continuing to work sustainably rather than driving dangerously rapid weight loss.
Weeks 36 to 72: Consolidation
Weight loss continues through week 72 in clinical trial data, though at a slower rate. SURMOUNT-1 showed meaningful additional weight loss occurred between weeks 36 and 72 for patients who remained on treatment. Dietary and lifestyle habits built during earlier phases become most important during this period.
SURMOUNT-1 clinical data by dose at 72 weeks
In the SURMOUNT-1 trial (New England Journal of Medicine, 2022), adults without diabetes who took tirzepatide alongside diet and activity advice lost an average of 15.0% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% on placebo, counting everyone who started treatment. Among people who stayed on treatment, the averages were 16.0%, 21.4% and 22.5%. Individual results vary.
| Dose | Average weight loss | ≥20% loss |
|---|---|---|
| 5mg | 15.0% | 30.0% |
| 10mg | 19.5% | 50.1% |
| 15mg | 20.9% | 56.7% |
| Placebo | 3.1% | 3.1% |
Counting everyone who started treatment. Sources: Jastreboff AM et al. N Engl J Med 2022 (SURMOUNT-1) and, for the ≥20% column, the tirzepatide US prescribing information.
What if you're not losing weight?
Not losing weight after 12 weeks at a stable dose requires a clinical review. Four possible reasons:
- Diet not sufficiently adjusted: Mounjaro reduces hunger but cannot override an unchanged high-calorie diet. Far more effective when dietary changes are made alongside it.
- Dose not yet at therapeutic level: results at 2.5mg are limited by design. If you are still at a low dose due to side effects, your pharmacist may discuss slower titration rather than remaining static.
- Individual variation: a minority of patients are slow responders at a given dose. Weight loss plateau for more than 8 weeks at 10mg or 15mg with dietary changes in place warrants clinical review.
- Other medications: some antipsychotics, corticosteroids, and insulin can significantly counteract weight loss and may need to be reviewed alongside Mounjaro.
Weight regain after stopping
In the SURMOUNT-4 trial (JAMA, 2024), 670 adults with obesity or overweight and without diabetes who had lost an average of 20.9% of their weight over 36 weeks on tirzepatide were randomly assigned to carry on or switch to placebo. Over the next 52 weeks, the weight of people who switched rose by an average of 14.0%, while those who carried on lost a further 5.5%. At 88 weeks, people who had switched were on average 9.9% below their starting weight, compared with 25.3% for those who carried on. Individual results vary. This reflects the chronic nature of obesity as a disease. Many patients treat Mounjaro as a long-term maintenance medication, as with antihypertensive therapy. This is not a failure. It is an appropriate response to a chronic condition.
"Weight loss on Mounjaro is cumulative, not immediate. Patients who understand this at the start are far more likely to reach the outcomes the clinical trials demonstrate, because they don't stop at week 6 expecting results that typically arrive at month 6."